Drug intelligence / Profile preview

BBI-03

Development stage: Preclinical
Lead developer: Fresh Tracks Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

BBI-03 is a preclinical, topically applied small-molecule inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), being developed for autoimmune and inflammatory skin diseases. As part of a DYRK1A inhibitor platform originally created by Voronoi and acquired by Brickell Biotech (now Fresh Tracks Therapeutics), BBI-03 is designed for local cutaneous delivery to modulate pathogenic immune signaling while limiting systemic exposure.[1][2][5][10] By selectively inhibiting DYRK1A, BBI-03 aims to restore immune balance in affected tissues, potentially addressing conditions such as atopic dermatitis and other dermatologic manifestations of immune dysregulation.[2][5][10]

Targets

DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)

Beyond the preview

Go deeper on BBI-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBI-03.

Explore the full profile